E2F1: A Drug Target / Disease Biomarker (G1869)

Target Name: E2F1

NCBI ID: G1869

E2F1

E2F1: A Drug Target / Disease Biomarker

E2F1, also known as SIRT1, is a non-coding RNA molecule that plays a crucial role in cellular processes. It is a key regulator of cell division, and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and aging. In recent years, researchers have been increasingly interested in studying E2F1 as a potential drug target or biomarker, due to its unique biology and its potential to modulate a wide range of cellular processes.

The E2F1 gene is located on chromosome 18, and it encodes a protein that is involved in the regulation of DNA replication, transcription, and apoptosis. E2F1 is a key regulator of the SIRT1 gene, which is a part of the superfamily of NAD+-dependent enzymes known as sirtuins. These enzymes have a well-documented ability to interact with NAD+, which is a molecule that plays a central role in a variety of cellular processes, including energy metabolism, signaling, and stress resistance.

One of the key functions of E2F1 is its role in regulating cell division. During G1 phase of the cell cycle, when the cell is preparing for cell division, E2F1 works to ensure that the DNA is fully replicated and that the cell is ready for cell division. It does this by binding to the transcription factor p21, which is involved in the regulation of cell division, and preventing it from from activating. This ensures that the cell division process is properly prepared, and that the cell is able to divide into two daughter cells that are genetically identical.

In addition to its role in cell division, E2F1 is also involved in the regulation of apoptosis, which is the process by which cells decide when they have had enough and decide to die. During apoptosis, E2F1 helps to ensure that the cell undergoes proper programmed cell death, by binding to the protein Bcl-2, which is involved in the regulation of apoptosis. Bcl-2 is a transcription factor that has been shown to play a role in the regulation of apoptosis in a variety of cell types, including cancer cells.

E2F1 has also been shown to be involved in a number of other cellular processes, including the regulation of cell signaling, DNA repair, and metabolism. For example, studies have shown that E2F1 can interact with the protein p53, which is involved in the regulation of DNA damage repair, and that it can modulate the levels of a variety of cellular signaling pathways, including TOR signaling, PI3K/Akt signaling, and the Wnt signaling pathway.

In addition to its role in cellular processes, E2F1 is also a potential drug target, due to its unique biology and its potential to modulate a wide range of cellular processes. One approach to studying E2F1 as a drug target is to use small molecules to inhibit its activity, and to test the effects of these inhibitors on cellular processes. For example, researchers have synthesized a variety of small molecules that can inhibit E2F1's activity, and have shown that these inhibitors have a wide range of effects, including the inhibition of cell division, the regulation of apoptosis, and the regulation of cell signaling.

Another approach to studying E2F1 as a drug target is to use RNA interference (RNAi) technology to knockdown the expression of E2F1 in cells, and to test the effects of these knockdowns on cellular processes. RNAi technology allows researchers to quickly and easily knockdown the expression of any gene of interest, and it has been a useful tool for studying the effects of drugs on cellular processes in a high-throughput manner.

In addition to its potential as a drug target, E2F1 is also a potential biomarker, due to its unique biology and its potential to modulate a wide range of cellular processes. For example, researchers have shown that E2F1 levels are often elevated in a variety of diseases, including cancer, neurodegenerative diseases, and aging. This suggests that E2F1 may be a useful biomarker for these diseases, and that its levels may be able to provide information about the severity and progression of these conditions.

Overall, E2F1 is a non-coding RNA molecule that plays a

Protein Name: E2F Transcription Factor 1

Functions: Transcription activator that binds DNA cooperatively with DP proteins through the E2 recognition site, 5'-TTTC[CG]CGC-3' found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication (PubMed:10675335, PubMed:12717439, PubMed:17704056, PubMed:17050006, PubMed:18625225, PubMed:28992046). The DRTF1/E2F complex functions in the control of cell-cycle progression from G1 to S phase (PubMed:10675335, PubMed:12717439, PubMed:17704056). E2F1 binds preferentially RB1 in a cell-cycle dependent manner (PubMed:10675335, PubMed:12717439, PubMed:17704056). It can mediate both cell proliferation and TP53/p53-dependent apoptosis (PubMed:8170954). Blocks adipocyte differentiation by binding to specific promoters repressing CEBPA binding to its target gene promoters (PubMed:20176812). Directly activates transcription of PEG10 (PubMed:17050006, PubMed:18625225, PubMed:28992046). Positively regulates transcription of RRP1B (PubMed:20040599)

The "E2F1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about E2F1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets